Heart disease in cats, particularly hypertrophic cardiomyopathy, progresses from subclinical to life-threatening. Welfare management focuses on monitoring, medication, and quality of life.
Feline heart disease presents unique welfare challenges because cats are excellent at masking subclinical disease. Many cats with HCM show no signs until acute decompensation — respiratory distress from pleural effusion or, most devastatingly, aortic thromboembolism. The welfare burden of these acute events is severe, and prevention through monitoring and medication is the primary welfare goal.
When congestive heart failure is diagnosed, furosemide therapy rapidly relieves the welfare burden of fluid accumulation. Most cats recover quickly from their first failure episode and can return to good quality of life with ongoing medication. Owner monitoring for respiratory rate at rest (target below 30 breaths/minute) is a validated, simple welfare monitoring tool that detects early decompensation.
ATE causes sudden hind limb paralysis and extreme pain and is one of the most distressing acute presentations in feline medicine. Welfare-informed decision-making at presentation — including whether to attempt treatment or pursue euthanasia — is ethically challenging and emotionally difficult for owners. Evidence supports that cats who survive the acute phase and show early limb recovery have reasonable quality of life, but prognosis guidance should be honest and welfare-centered.